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Introduction
The Hh-signaling pathway regulates cell differentiation, organ patterning, and cell proliferation (1) . In the absence of a ligand the activity of the Hh-pathway is inhibited due to an interaction between the Hh receptor Ptch and its partner Smo. Binding of Hh to Ptch, inactivating Ptch mutations, or activating Smo mutations may suspend this inhibition, resulting in the transcription of target genes including Gli1 (1) . Thus aberrant (e.g. mutationdriven) Hh-signaling results in tumor formation (2) . One prominent example is BCC, the most frequent tumor entity in humans, with active Hh-signaling due to mutations in Ptch.
Today the inhibition of the Hh-pathway is considered as a promising strategy in the treatment of these tumors. Thus specific Smo inhibitors such as cyclopamine and GDC0449 have been tested in several small, non-randomized clinical trials (2) . GDC0449 was recently shown to elicit antitumoral effects in 18 out of 33 patients with locally-advanced or metastatic BCC (3) .
It remains to be elucidated if these promising results will be confirmed in a prospective, randomized and controlled study and if Hh targeting alone will be sufficient. In this context, a recent report describes resistance to GDC0449 due to a therapy-associated Smo mutation (4) .
As with other tumors, therapy of those associated with abnormal Hh-signaling may require targeting of additional signaling pathways.
Vitamin D 3 and its derivatives (e.g. EB1089; Paricalcitriol) are known to have antitumoral effects on different cancer types (5) including squamous cell carcinoma (6, 7) or on hyperproliferative skin diseases such as psoriasis (8, 9) . These effects comprise G0/G1 arrest, Calcitriol is produced from vitamin D 3 by two hydroxylation steps in the liver and kidney, respectively, and to a lesser extent in other organs and in tumor cells (5) . Through binding to Vdr, calcitriol regulates the transcription of Vdr target genes (5) . This so-called "genomic" calcitriol/Vdr-signaling regulates a variety of physiological processes including cellular differentiation, especially in the skin (10, 11) , proliferation, and apoptosis, and can be monitored by measuring transcription of the calcitriol metabolizing enzyme 24-hydroxylase (5). In addition, calcitriol elicits rapid, so-called "non-genomic" (i.e. transcriptionindependent) effects such as calcium influx (5) . One would expect that inactivation of Ptch results in a disrupted secretion of this derivative.
This should result in a potential deprivation of the vitamin D 3 derivative, and in lack of Smoinhibition. If this hypothesis is true, the concerted action of active Hh-and inactive Vdrsignaling may be the driving forces leading to enhanced cell proliferation, compromised differentiation and ultimately to tumor formation. It follows that it should be possible to revert or at least to impede these processes by administration of the respective vitamin D 3 derivative. 
Material and methods

Compounds
Calcitriol (Sigma-Aldrich, Germany) and cyclopamine (Toronto Research Chemicals Inc., Canada) were dissolved in ethanol (EtOH). Final concentrations for in vitro experiments are indicated in the respective experiments and correspond to those normally used in cell culture (5, 14, 15) . For in vivo use, calcitriol was diluted individually for each animal in 20 µl EtOH/1200 µl sterile sunflower oil (Sigma-Aldrich) to obtain a final concentration of 40 or 100 ng/kg in 50 µl.
Animals and treatment of tumor-bearing Ptch flox/flox ERT2 +/-mice with calcitriol
Conditional Ptch flox/flox ERT2 +/-mice were randomized into 2 groups and BCC were induced in all animals by intramuscular injection of 100 µg tamoxifen as described (13, 16) . Tumors of this animal model lack the expression of wt Ptch alleles and are therefore deficient in Ptch (13, 17) . Starting points of the daily intraperitoneal (i.p.) treatment with 100 ng/kg calcitriol or vehicle were day 0 or 60 after BCC induction. Treatment of each cohort was conducted until day 90 after BCC induction. For RNA isolation and histological examinations skin samples were collected from tails 24 h after the last calcitriol injection.
Mice were fed with calcium-and phosphate-reduced and vitamin D 3 -free food (ssniff Spezialdiaeten, Soest, Germany; E15312-14) (18) one week before and during the injection period, and for one week thereafter.
All animals were treated and housed in accordance with the German animal protection law.
Measurement of tumor size
BCC size was measured on hematoxylin and eosin (H&E) stained sections using the area calculation tool of the software CellF (Olympus Soft Imaging Solutions GmbH; Germany). Analysis of calcium blood serum values 100 µl of blood were collected from the retroorbital plexus. Serum calcium concentrations were measured using an O-cresolphthaleine-based assay (cobas, Roche Diagnostics GmbH, Germany).
Histopathology and Immunohistochemistry
BCC and normal skin (NS) from the tail were embedded in paraffin for histological analyses or were used for isolation of total RNA. The identity of BCC was confirmed by examination of H&E stained sections. Paraffin sections were stained using an anti-Ki67-and anti-active caspase 3-antibody as described (19) . The murine BCC cell line ASZ001 was established from UV-induced BCC of Ptch neo12/+ mice and maintained as described (22) . All cell lines have been tested and authenticated before using by genotyping PCRs on genomic DNA as described (13, 20, 21 For gene expression analysis or 5-bromo-2'-deoxyuridine (BrdU) incorporation and caspase assays, 100,000 or 4,000 cells/well were seeded in 6-well-and 96-well-plates, respectively. Cell proliferation was measured after BrdU-pulsing for the last 22 h using a Cell Proliferation
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BrdU ELISA (Roche Diagnostics GmbH).
Activity of Caspase 3 and 7 was measured using the Caspase-Glo Glycerol-3-phosphate dehydrogenase (mGapd), wildtype (wt) Ptch transcripts (derived from the non-recombined Ptch flox locus) and Ptch del transcripts were detected by RT-PCR as described in (13, 24) . and rabbit anti-mouse IgG (1:5000; GE Healthcare, Germany), respectively. Signals were detected by using ECL+ reagent (GE Healthcare).
Protein extraction and Western blot
Statistics
Mann-Whitney-U testing was performed to determine the significance of the results. 
ERT2
+/-mice express elevated Vdr levels compared to normal murine skin (Fig. 1A) .
To Calcitriol led to a significant induction of Cyp24a1 transcription (Fig. 1C) , which was consistent with the presence of Vdr in BCC (Fig 1A) . In addition, calcitriol decreased Gli1 expression, thus indicating an inhibition of the Hh-signaling pathway. As expected, cyclopamine did not induce Cyp24a1 transcription but repressed Gli1 expression. The repressive effect was more pronounced than that achieved with calcitriol (Fig. 1C) .
Next, we assessed the antiproliferative effects of calcitriol. As revealed by anti-Ki67 antibody staining, calcitirol inhibited proliferation of tumor cells in BCC-bearing skin punches (Fig.   1D ). Most interestingly, the antiproliferative effect of calcitriol was more pronounced than that achieved with the Hh-specific inhibitor cyclopamine (Fig. 1D) .
Similar results were obtained, when the BCC-derived cell line ASZ001 was incubated with 10 nM calcitriol or with 10 µM cyclopamine for 48 h. As shown in figure 1E both substances efficiently inhibited Hh-signaling. However, only calcitriol significantly inhibited BrdUincorporation in these cells (Fig. 1F) . Inhibition of proliferation apparently was not 
accompanied by an increase in apoptosis, as calcitriol had no effect on caspase 3/7 activity (Fig. 1G) .
Together, these results show that calcitriol efficiently inhibits the Hh-signaling pathway and activates Vdr-signaling in BCC. In contrast to cyclopamine only calcitriol mediated antiproliferative effects in BCC, even though cyclopamine more efficiently inhibits Hhsignaling. Preliminary studies, in which mice were treated daily with 40 ng/kg calcitriol starting at the day of tamoxifen injection for 90 subsequent days (days 0-90), did not result in an induction of Vdr-signaling or differentiation (data not shown). Therefore, we increased the daily calcitriol dose to 100 ng/kg. Calcitriol treatment was started either immediately (day 0) or 60 days after BCC initiation (n 60-90d =6; n 0-90d =4). Vehicle treated animals (n vehicle =17) served as controls. The treatment was continued until day 90, when all mice were sacrificed (see Fig.   2A ).
Calcitriol treatment of
Calcitriol therapy led to a significant increase in serum calcium concentrations ( Fig. 2A) without causing weight loss, hypercalcemia-driven kidney damage or signs of nephrocalcinosis (data not shown). This indicates that the treatment induced calcitriol-specific systemic effects without causing toxicity. Tumor areas on H&E-stained skin sections in mice treated on days 0-90, but not on days 60-90, were significantly decreased when compared to the vehicle treated group (Fig. 2B, C) . Furthermore, calcitriol inhibited tumor cell proliferation as measured by Ki67 + cells in tumors treated on days 0-90 (Fig. 2D ). This was accompanied by a significant decreased expression of Hh-pathway target genes Gli1 and Gli2 (28) (29) (30) in BCC treated for days 0-90 (Fig. 2E) . Consistent with the results from our in vitro studies no significant increase of caspase 3 positive BCC cells were observed (data not shown). Moreover, calcitriol treatment resulted in a substantial activation of Vdr-signaling as revealed by an enhanced expression of the immediate Vdr-target gene Cyp24a1 (Fig. 2E ).
Finally, a significantly increased expression of the keratinocyte differentiation markers and Vdr-target genes Tgm1 and K10 were detected (Fig. 2F ). Whereas both differentiation markers can be induced by active Vdr-signaling, K10 expression also depends on Hhsignaling activity (10, 29, (31) (32) (33) (34) .
In summary, our data demonstrate that calcitriol significantly inhibits proliferation and induces cellular differentiation of Ptch-associated BCC in vivo. Moreover, this response is accompanied by activation of Vdr-and inactivation of the Hh-signaling pathways.
Calcitriol inhibits Hh-signaling downstream of Ptch but upstream of Gli1
Vitamin D 3 has been shown to inhibit Hh-signaling at the level of Smo (12, 35, 36 Upon tamoxifen-induced activation of ERT2 recombinase the exons 8 and 9 of the floxed Ptch alleles are excised. This results in the expression of an aberrant, non-functional Ptch transcript (Fig. 3A) .
In Ptch flox/flox ERT2 +/-fibroblasts both, the treatment with Shh-N-CM or the tamoxifen-induced Ptch mutation result in activation of Hh-signaling as revealed by induction of Gli1 expression (Fig. 3B) calcitriol significantly inhibited Gli1 expression (Fig. 3B) . Similar results were obtained with the validated Smo inhibitor cyclopamine (Fig. 3B ). These data show that similar to cyclopamine, calcitriol inhibits Hh-signaling downstream of Ptch.
The effects of calcitriol were also tested in Smo -/-cells, which express basal Gli1 levels. Due to lack of Smo, Hh-signaling cannot be activated in these cells by incubation with Shhconditioned medium (37). However, in these cells Hh-pathway activity can be restored by transfection with a hSMO expression plasmid.
As shown in figure 3C , calcitriol did not influence basal Gli1 expression levels in Smo -/-cells (Fig. 3C) . However, calcitriol efficiently inhibited Hh-signaling after restoration of Hhpathway activity upon transfection with hSMO. These results are similar to those obtained with cyclopamine ( Fig. 3C ) and show that calcitriol normally inhibits Gli1 expression at the level of Smo.
Calcitriol inhibits Hh-signaling in a Vdr-independent manner
Next, we tested whether calcitriol-mediated inhibition of the Hh-signaling pathway is independent of Vdr-signaling. For this purpose we used Vdr -/-fibroblast (21) . In these cells Vdr-signaling is completely abrogated, since incubation with calcitriol does not result in the induction of the Vdr-target Cyp24a1 (Fig. 4A) . As revealed by Gli1 expression, incubation of the cells with Shh-N-CM resulted in induction of Hh-pathway activity (Fig. 4A) , which was significantly inhibited by addition of calcitriol or by the control substance cyclopamine ( (Fig. 4B) , qRT-PCR and by a significantly lower Cyp24a1 expression after calcitriol treatment in comparison to the controls (Fig. 4C, D a downregulation of Gli1 expression (Fig. 4C, D) . These data show that calcitriol-mediated inhibition of the Hh-signaling pathway occurs independently of the Vdr. 
Discussion
The active form of vitamin D 3 , calcitriol, is rapidly gaining importance in oncology due to its antiproliferative and differentiation-inducing effects combined with its low toxicity (5).
Our work extends the range of calcitriol tumor targets to those induced by an abnormal activity of the Hh-signaling pathway (summarized in Fig. 5) . Specifically, we show that calcitriol inhibits growth of BCC induced by deletion of the Hh receptor Ptch. This is accompanied by the expression of relevant cell differentiation markers. Our data suggest that calcitriol could be a valuable supplement or even alternative to the established treatments of BCC, the most common tumor in humans, associated with aberrant Hh-pathway activity.
As assessed by reduced Gli1 transcription, calcitriol inhibits canonical Hh-signaling independently of Vdr-signaling and downstream of Ptch (Fig. 5 ). An obvious molecular target of this Vdr-independent effect of calcitriol is Smo, since Smo-deficient cells (unlike those reconstituted with Smo or Ptch-deficient ones) show no decreased Gli1 transcription in response to this substance. A similar observation has been made for the inactive form of calcitriol, vitamin D 3 (12) . Nevertheless, whether calcitriol directly binds to Smo should be addressed in future studies.
Besides inhibition of Hh-signaling pathway, calcitriol inhibits proliferation and increases the expression of skin differentiation marker in BCC. The latter effects are also induced by calcitriol in skin of patients with hyperproliferative skin diseases such as psoriasis (6-9, 34, 38) . Calcitriol treatment specifically results in inhibition of proliferation of psoriatic skin and induction of differentiation of keratinocytes (9, 39, 40) . Similarly to BCC, psoriatic skin also expresses high levels of the Hh-target gene Gli1 (41) . These facts raise the question whether calcitriol mediates its antiproliferative effects and differentiation stimuli via activation of Vdrsignaling or rather via inhibition of the Hh-signaling pathway. A clue might come from our 
present study: Our in vitro study shows that calcitriol has a significantly stronger antiproliferative effect on BCC than the pure Smo inhibitor cyclopamine, even though the latter substance inhibits Hh-signaling more efficiently (see Fig. 1D and 1F) . Together with the fact that both calcitriol (present study) and cyclopamine (42) inhibit BCC proliferation in vivo, it is possible that calcitriol exerts its antiproliferative effects via both signaling pathways (e.g. by inhibition or activation of Hh-or Vdr-signaling, respectively). On the other hand, differentiation of calcitriol-treated BCC is probably unrelated to inhibition of the canonical Hh-signaling pathway because cylopamine never has been reported to induce the expression of keratinocyte differentiation markers in BCC. More likely, calcitriol induces BCC differentiation via Vdr-signaling, which is supported by the increased expression of the Vdrtarget genes Cyp24a1 and Tgm1 (see Fig. 2F ).
Antiproliferative and Hh-signaling inhibitory properties have also been described for the inactive form of calcitriol, vitamin D 3 , on murine BCC in vitro and in vivo (35) . In contrast to calcitriol, vitamin D 3 did not affect differentiation in BCC, although it was topically applied at high concentrations. Supposedly the treatment period using vitamin D 3 (i.e. 30 days) may have been too short to induce Vdr-signaling and thus a differentiation response. This suggestion is based on a comparison with our study, in which a 30 days calcitriol application also had no significant effects on these processes (see BCC treated for days 60-90, Fig. 2B-E) .
Finally, a new model of tumorigenesis driven by Ptch-deficiency may emerge from our study. for Gli1, Cyp24a1, Tgm1 and K10 expression were set to 1. One Asterisk: p=0.06; two Asterisks: p<0.05; error bars: mean+/-SD. 
